Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

GLP-1 receptor agonists and herpes risk in patients with diabetes

Association of GLP-1 receptor agonists with herpes risks in diabetes mellitus: a target trial emulation

BMC Medicine

Citation & Authors

BMC Med. 2026;24:144.

Chi-Hsien Huang; I-Hui Chiang; I-Cheng Lu; Po-Hsuan Lai; Pei-Lun Liao; Jing-Yang Huang; Ming-Ta Hsieh; Chi-Wei Lin; I-Ting Liu; James Cheng-Chung Wei

ABSTRACT · RESEARCH SUMMARY

Research summary

TriNetX analyses included 95,190 matched pairs of GLP-1/DPP-4 users and 82,789 pairs of GLP-1/SGLT2 users. GLP-1 drugs were associated with higher risks of both herpes simplex and herpes zoster than either comparator; the HRs versus DPP-4 inhibitors were 1.387 and 1.294, respectively. Lower risks were observed among vaccinated patients, but causal relationships between these drugs and infection require further confirmation.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗

Key findings

The comparison of GLP-1 receptor agonists with DPP-4 inhibitors included 95,190 matched pairs, and the comparison with SGLT2 inhibitors included 82,789 pairs. In the primary analysis, GLP-1 receptor agonists were associated with a higher risk of herpes zoster: HR 1.294 (95% CI 1.203–1.392) versus DPP-4 inhibitors and HR 1.180 (95% CI 1.085–1.284) versus SGLT2 inhibitors.

These are observational associations and do not establish causal relationships between medication and infection. Some intention-to-treat sensitivity analyses did not reproduce the difference in the composite herpes outcome, and further validation is needed.